RNS Number : 3136X
Shield Therapeutics PLC
26 April 2019

Shield Therapeutics plc
("Shield" or the "Company")

PDMR Acquisition of Shares

London, UK, 26 April 2019, Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that Mark Sampson, Chief Medical Officer, has acquired 22,875 Ordinary Shares in the Company on 25 April 2019 at an average price of 87.4 pence per share. Mrs Julie Sampson, wife of Mark Sampson, also acquired 22,042 Ordinary Shares in the Company on 25 April 2019 at an average price of 90.7 pence per share. Following the transaction, Dr Sampson has a beneficial interest (including those of his connected persons) in 83,701 shares, representing 0.01% of the Company's issued share capital.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	**Details of the person discharging managerial responsibilities/person closely associated**	
a)	Name	Mark Raymond Sampson
2	**Reason for the notification**	
a)	Position/status	Chief Medical Officer
b)	Initial notification/ Amendment	Initial Notification
3	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a)	Name	Shield Therapeutics plc
b)	LEI	213800G74QWY15FC3W71

4	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293
b)	Nature of the transaction	Acquisition of Ordinary Shares
c)	Price(s) and volume(s)	87.4 pence per Ordinary Share Volumes: 22,875
d)	Aggregated information -Aggregated volume -Price	N/A
e)	Date of the transaction	22,875 Ordinary Shares - 25 April 2019
f)	Place of the transaction	London Stock Exchange, AIM Market

1	**Details of the person discharging managerial responsibilities/person closely associated**	
a)	Name	Julie Karen Sampson
2	**Reason for the notification**	
a)	Position/status	PCA

b)	Initial notification/ Amendment	Initial Notification
3	**Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor**	
a)	Name	Shield Therapeutics plc
b)	LEI	213800G74QWY15FC3W71
4	**Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted**	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293
b)	Nature of the transaction	Acquisition of Ordinary Shares
c)	Price(s) and volume(s)	90.7 pence per Ordinary Share Volumes: 22,042
d)	Aggregated information -Aggregated volume -Price	N/A
e)	Date of the transaction	22,042 Ordinary Shares - 25 April 2019
f)	Place of the transaction	London Stock Exchange, AIM Market

For further information please contact:

Shield Therapeutics plc www.shieldtherapeutics.com
Carl Sterritt, Chief Executive Officer +44 (0)20 7186 8500
Tim Watts, Chief Financial Officer

Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden +44 (0)20 7418 8900

Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780
or shield@walbrookpr.com
Paul McManus / Helen Cresswell +44 (0)7980 541 893 / +44 (0)7841 917 679

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019. For more information please visit www.shieldtherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations and include statements related to the timing of future results of Feraccru trials and the timing and success of the Group's regulatory plans and commercial strategy for Feraccru. These statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results, performance or achievements to be materially different from management's expectations expressed or implied by the forward-looking statements, including, but not limited to, risks associated with the regulatory approval process, the Group's business and results of operations, competition and other market factors. The forward-looking statements made in this press release represent management's expectations as of the date of this press release, and except as required by law, the Group disclaims any obligation to update any forward-looking statements contained in this release, even if subsequent events cause our views to change.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHDQLFLKZFBBBL